keyword
https://read.qxmd.com/read/38022102/a-rare-case-of-hydralazine-induced-diffuse-alveolar-hemorrhage
#21
Angela Xue, Adele Bernard, Vanessa Moreno, Lindsey Phillips, Evan Raff
Hydralazine-induced anti-neutrophil cytoplasmic antibody (ANCA) vasculitis may occur any time after hydralazine initiation. General internists should recognize diffuse alveolar hemorrhage (DAH) as a rare complication of this condition, as early treatment reduces the associated high risk of mortality. We describe the case of an 82-year-old female with diastolic heart failure who presented with a one-month history of worsening dyspnea on exertion and a one-week history of scant hemoptysis and fatigue. Her medications included aspirin and hydralazine...
October 2023: Curēus
https://read.qxmd.com/read/38021694/hydralazine-induced-anti-neutrophil-cytoplasmic-antibody-anca-associated-vasculitis
#22
Victoria Echevarria, Ednord Pierre, Jorge Quiros, Parham Eftekhari
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises several conditions involving vascular destruction that extends into tissue necrosis. There are several autoimmune and environmental causes implicated in the disease progression; among these is drug-induced vasculitis caused by hydralazine use. Hydralazine-induced vasculitis is an uncommon potential complication of the medication and can progress to multisystem involvement and eventually advance to end-organ damage and renal failure...
October 2023: Curēus
https://read.qxmd.com/read/37989321/in-vivo-ameliorative-effects-of-vitamin-e-against-hydralazine-induced-lupus
#23
JOURNAL ARTICLE
Fiona Muthoni Githaiga, George Isanda Omwenga, Mathew Piero Ngugi
OBJECTIVE: In this study, we investigated the in vivo ameliorative effects of vitamin E in a hydralazine-induced lupus model, which closely resembles SLE in humans. We aim to shed light on its potential as a therapeutic agent for managing SLE. METHODS: Forty BALB/c mice were used in this study. Hydralazine hydrochloride was orally administered in a concentration of 25 mg/kg to the five mice groups once weekly for a period of 5 weeks to induce a lupus-like condition...
November 2023: Lupus Science & Medicine
https://read.qxmd.com/read/37958938/effect-of-hydralazine-on-angiotensin-ii-induced-abdominal-aortic-aneurysm-in-apolipoprotein-e-deficient-mice
#24
JOURNAL ARTICLE
Yutang Wang, Owen Sargisson, Dinh Tam Nguyen, Ketura Parker, Stephan J R Pyke, Ahmed Alramahi, Liam Thihlum, Yan Fang, Morgan E Wallace, Stuart P Berzins, Ernesto Oqueli, Dianna J Magliano, Jonathan Golledge
The rupture of an abdominal aortic aneurysm (AAA) causes about 200,000 deaths worldwide each year. However, there are currently no effective drug therapies to prevent AAA formation or, when present, to decrease progression and rupture, highlighting an urgent need for more research in this field. Increased vascular inflammation and enhanced apoptosis of vascular smooth muscle cells (VSMCs) are implicated in AAA formation. Here, we investigated whether hydralazine, which has anti-inflammatory and anti-apoptotic properties, inhibited AAA formation and pathological hallmarks...
November 3, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37897153/hydralazine-combined-with-conventional-therapy-improved-outcomes-in-severe-systolic-dysfunction-and-mitral-regurgitation
#25
JOURNAL ARTICLE
Shih-Hung Hsiao, Chao-Sheng Hsiao, Jau-Wen Shiau, Kuan-Rau Chiou
AIMS: Patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) accompanied by significant mitral regurgitation (MR) had poor outcome. Several vasodilator trials showed neutral results. We aimed to investigate the effect of early up-titration of hydralazine combined with conventional treatment in acute HF with severe systolic dysfunction and significant MR. METHODS AND RESULTS: The study was open-labelled, one-to-one ratio randomized designed...
October 27, 2023: ESC Heart Failure
https://read.qxmd.com/read/37868488/the-pathophysiology-and-new-advancements-in-the-pharmacologic-and-exercise-based-management-of-heart-failure-with-reduced-ejection-fraction-a-narrative-review
#26
REVIEW
Snaiha I Narayan, Giselle V Terre, Rutvi Amin, Keshvi V Shanghavi, Gayathri Chandrashekar, Farhana Ghouse, Binish A Ahmad, Gowri N S, Christena Satram, Hamna A Majid, Danielle K Bayoro
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome whose management has significantly evolved based on the pathophysiology and disease process. It is widely prevalent, has a relatively high mortality rate, and is comparatively more common in men than women. In HFrEF, the series of maladaptive processes that occur lead to an inability of the muscle of the left ventricle to pump blood efficiently and effectively, causing cardiac dysfunction. The neurohormonal and hemodynamic adaptations play a significant role in the advancement of the disease and are critical to guiding the treatment and management of HFrEF...
September 2023: Curēus
https://read.qxmd.com/read/37857042/treatment-of-acute-onset-hypertension-in-pregnancy-a-network-meta-analysis-of-randomized-controlled-trials-comparing-anti-hypertensives-and-route-of-administration
#27
REVIEW
Adithya D Bhat, Paige M Keasler, Lavanya Kolluru, Michael M Dombrowski, Arvind Palanisamy, Preet Mohinder Singh
BACKGROUND: Consensus on the relative efficacy of available antihypertensive agents used in pregnancy is lacking. OBJECTIVE: To compare treatment success with antihypertensives and categorize by route of administration. SEARCH STRATEGY: MEDLINE, Embase, PubMed, Web of Science, Scopus, CINAHL, and clinicaltrials.gov were searched without date restriction. DATA COLLECTION: Peer-reviewed randomized controlled trials (RCTs) comparing pharmacologic agents used to treat hypertension in parturients were included...
October 17, 2023: Pregnancy Hypertension
https://read.qxmd.com/read/37840953/antihypertensive-treatment-with-hydrochlorothiazide-hydralazine-combination-aggravates-medial-vascular-calcification-in-ckd-rats-with-mineral-bone-disorder
#28
JOURNAL ARTICLE
Richard Larivière, Roth-Visal Ung, Sylvain Picard, Darren E Richard, Fabrice Mac-Way, Mohsen Agharazii
BACKGROUND: Arterial stiffness and medial vascular calcification, leading to isolated systolic blood pressure (BP), are major cardiovascular risk factors in patients with chronic kidney disease (CKD) and mineral bone disorders (MBD). The impact of BP on MBD-induced medial vascular calcification in CKD remains uncertain. We investigated whether BP reduction improves arterial stiffness and medial vascular calcification in a rat model of CKD-MBD. METHODS: CKD was induced in Wistar rats by subtotal nephrectomy...
2023: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/37806366/sgx523-causes-renal-toxicity-through-aldehyde-oxidase-mediated-less-soluble-metabolite-formation-in-chimeric-mice-with-humanized-livers
#29
JOURNAL ARTICLE
Shotaro Uehara, Masahiko Yasuda, Yuichiro Higuchi, Nao Yoneda, Kenji Kawai, Masami Suzuki, Hiroshi Yamazaki, Hiroshi Suemizu
SGX523 is a c-Met tyrosine kinase inhibitor that failed in clinical trials because of renal toxicity caused by crystal deposits in renal tubules. SGX523 is metabolized by aldehyde oxidase (AOX) in a species-dependent manner to the considerably less soluble 2-quinolinone-SGX523, which is likely involved in the clinically observed obstructive nephropathy. This study investigated the metabolism and renal toxicity of SGX523 in chimeric mice with humanized livers (humanized-liver mice). The 2-quinolinone-SGX523 formation activity was higher in humanized-liver mouse and human hepatocytes than in mouse hepatocytes...
October 6, 2023: Toxicology Letters
https://read.qxmd.com/read/37768997/synergistic-combination-of-doxorubicin-with-hydralazine-and-disulfiram-against-mcf-7-breast-cancer-cell-line
#30
JOURNAL ARTICLE
Zainab Lafi, Walhan Alshaer, Lobna Gharaibeh, Dana A Alqudah, Baidaa AlQuaissi, Banan Bashaireh, Abed Alqader Ibrahim
Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adverse effects compared to chemotherapy alone. In the present study, a combination of doxorubicin (DOX) with hydrazine (Hyd) and disulfiram (Dis), as a triple treatment, was evaluated against wild-type and DOX-resistant MCF-7 breast cancer cell line...
2023: PloS One
https://read.qxmd.com/read/37759279/how-do-we-define-high-and-low-dose-intensity-of-heart-failure-medications-a-scoping-review
#31
JOURNAL ARTICLE
Min Ji Kwak, Qian Wang, Chukwuma Onyebeke, Travis Holder, Parag Goyal, Rajender Aparasu, Abhjeet Dhoble, Holly M Holmes
BACKGROUND: Older adults with heart failure often experience adverse drug events with high doses of heart failure medications. Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician on which symptoms to look for, whether from overdosing or underdosing. However, the current guideline does not provide sufficient information about the dose intensity below the target dose. Furthermore, the definition of high or low-intensity heart failure medication is unclear, and there is no consensus...
September 27, 2023: BMC Cardiovascular Disorders
https://read.qxmd.com/read/37664446/diffuse-hydralazine-associated-vasculitis-with-pathergy-an-overlapping-picture-of-sweet-syndrome-and-bullous-vasculitis
#32
Sara Banbury, Corinne Rauck, Eric E Morgan, Maria F Arisi, Juliana Berk-Krauss, Timothy Buckey, Olajumoke Fadugba, Misha Rosenbach
No abstract text is available yet for this article.
September 2023: JAAD Case Reports
https://read.qxmd.com/read/37661037/hydralazine-inhibits-neuroinflammation-and-oxidative-stress-in-app-ps1-mice-via-tlr4-nf-%C3%AE%C2%BAb-and-nrf2-pathways
#33
JOURNAL ARTICLE
Yu Wang, Jiayang Zou, Yue Wang, Jinyang Wang, Xiaoming Ji, Tianyun Zhang, Yun Chu, Rui Cui, Guoliang Zhang, Geming Shi, Yuming Wu, Yunxiao Kang
Alzheimer's disease (AD) is a common chronic progressive neurodegenerative disorder, and curative treatment has not been developed. The objective of this study was to investigate the potential effects of hydralazine (Hyd, a hypertension treatment drug) on the development process of AD and its mechanisms. We treated 6-month-old male APP/PS1 mice with Hyd for 5 weeks, measured changes in behavior and pathological status, and analyzed differences in gene expression by RNA sequencing. The results demonstrated that Hyd improved cognitive deficits and decreased amyloid beta protein deposition in the cortex and hippocampus, while RNA sequencing analysis suggested that the regulation of neuroinflammation and energy metabolism might play pivotal roles for Hyd's beneficial effects...
September 1, 2023: Neuropharmacology
https://read.qxmd.com/read/37631362/the-influence-of-wet-granulation-parameters-on-the-compaction-behavior-and-tablet-strength-of-a-hydralazine-powder-mixture
#34
JOURNAL ARTICLE
Oliver Macho, Ľudmila Gabrišová, Adam Guštafík, Kristian Jezso, Martin Juriga, Juraj Kabát, Jaroslav Blaško
The aim of this paper was to describe the influence of high-shear wet granulation process parameters on tablet tensile strength and compaction behavior of a powder mixture and granules containing hydralazine. The hydralazine powder mixture and eight types of granules were compacted into tablets and evaluated using the Heckel, Kawakita and Adams analyses. The granules were created using two types of granulation liquid (distilled water and aqueous solution of polyvinylpyrrolidone), at different impeller speeds (500 and 700 rpm) and with different wet massing times (without wet massing and for 2 min)...
August 16, 2023: Pharmaceutics
https://read.qxmd.com/read/37614273/comparing-intravenous-labetalol-and-intravenous-hydralazine-for-managing-severe-gestational-hypertension
#35
JOURNAL ARTICLE
Eustace Ehikioya, Okelue E Okobi, Maame Akosua E Beeko, Rafia Abanga, Namtor Nicole I Abah, Lilian Briggs, Patience N Nwimo, Papa Kwame A Beeko, Onyinyechukwu B Nwachukwu, Caroline C Okoroafor
Background Hypertensive disorders of pregnancy are the leading causes of both maternal morbidity and maternal mortality. Hypertensive disorders are acute obstetric emergencies, which refer to various life-threatening medical challenges known to develop during pregnancy, labor, and delivery, requiring urgent attention to reduce blood pressure (BP) for the benefit of the affected mothers and infants. Hydralazine and labetalol have been widely used as the first-line medications in the management of severe hypertension during pregnancy...
July 2023: Curēus
https://read.qxmd.com/read/37576545/therapies-for-patients-with-coexisting-heart-failure-with-reduced-ejection-fraction-and-non-alcoholic-fatty-liver-disease
#36
REVIEW
Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura
Heart failure with reduced ejection fraction (HFrEF) and nonalcoholic fatty liver disease (NAFLD) are two common comorbidities that share similar pathophysiological mechanisms. There is a growing interest in the potential of targeted therapies to improve outcomes in patients with coexisting HFrEF and NAFLD. This manuscript reviews current and potential therapies for patients with coexisting HFrEF and NAFLD. Pharmacological therapies, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoids receptor antagonist, and sodium-glucose cotransporter-2 inhibitors, have been shown to reduce fibrosis and fat deposits in the liver...
July 26, 2023: World Journal of Cardiology
https://read.qxmd.com/read/37576371/determinants-of-visit-to-visit-systolic-blood-pressure-variability-among-ghanaians-with-hypertension-and-diabetes-mellitus
#37
JOURNAL ARTICLE
Fred S Sarfo, Nana K Ayisi-Boateng, Samuel B Nguah, Osei Sarfo-Kantanka, Collins Kokuro, Hanson Ababio, Yaw Adu-Boakye, Bruce Ovbiagele
OBJECTIVE: To identify the determinants of systolic blood pressure variability (SBPV) among Ghanaians. DESIGN: We undertook a secondary analysis of data collected in a prospective study. SETTING: The study involved patients with hypertension and or diabetes receiving care in five hospitals in Ghana. MAIN OUTCOME MEASURES: We assessed determinants of SBPV among 2,785 Ghanaian patients. We calculated the standard deviation (SD) of systolic BP recordings of 3 to 10 visits per patient over 18 months as a measure of SBPV...
January 2023: Ghana Medical Journal
https://read.qxmd.com/read/37564481/epidemiological-profile-of-neonates-in-hearing-screening-at-a-maternity-of-a-tertiary-hospital-in-the-state-of-santa-catarina-brazil
#38
JOURNAL ARTICLE
Juan Diego Gimenes Lopes, Carolina Disconzi Dallegrave, Nadine Hellmann Delfino, Rúbia Lauxen, Taise Marcelino, Carlos Eduardo Monteiro Zappelini
Introduction  The newborn hearing screening (NHS) test aims the early diagnostic of hearing deficits that may also harm the full development of communication and learning of the affected child. Objective  Trace the clinical and epidemiological profile of children born between July 2016 and July 2019; in addition to the outcome of the NHSs and factors related to failure in the hearing tests at a maternity of a tertiary hospital in Santa Catarina, Brazil. Methods  The present is a cross-sectional study...
July 2023: International Archives of Otorhinolaryngology
https://read.qxmd.com/read/37558864/hydralazine-promotes-central-nervous-system-recovery-after-spinal-cord-injury-by-suppressing-oxidative-stress-and-inflammation-through-macrophage-regulation
#39
JOURNAL ARTICLE
Xin Quan, Teng Ma, Kai Guo, Huan Wang, Cai-Yong Yu, Chu-Chu Qi, Bao-Qiang Song
OBJECTIVE: This study aims to investigate the effects of hydralazine on inflammation induced by spinal cord injury (SCI) in the central nervous system (CNS) and its mechanism in promoting the structural and functional recovery of the injured CNS. METHODS: A compressive SCI mouse model was utilized for this investigation. Immunofluorescence and quantitative real-time polymerase chain reaction were employed to examine the levels of acrolein, acrolein-induced inflammation-related factors, and macrophages at the injury site and within the CNS...
August 10, 2023: Current Medical Science
https://read.qxmd.com/read/37545898/comparison-of-efficacy-of-intravenous-labetalol-and-intravenous-hydralazine-for-management-of-pre-eclampsia-in-pregnant-women
#40
JOURNAL ARTICLE
Mauzma Kausar, Samia Husain, Rubina Hussain
OBJECTIVES: To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia. METHODOLOGY: This comparative study was conducted at the Department of Obstetrics and Gynecology at Ziauddin University Hospital, Karachi from1st June 2019 to 30th June 2020. Total 208 pregnant women having severe pre-eclampsia (systolic pressure ≥160 mmHg and diastolic pressure ≥110mmHg) were included in study...
March 2023: African Health Sciences
keyword
keyword
72807
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.